Skip to NavigationSkip to content

HHS to fund production of MSD's Ebola vaccine V920

Published on 22/08/19 at 10:50am

The US Department of Health and Human Services (HHS) has said it will fund the production of MSD’s investigational Ebola vaccine V920 in response to the ongoing Ebola outbreak in the Democratic Republic of Congo (DRC).

At least 1,900 have died from Ebola over the past year in the DRC, as the central African country experiences the second worst Ebola outbreak in history after the outbreak in West Africa in 2014-16 that killed 11,300.

The HHS has said it will give $23 million to MSD to produce the vaccine. The sum brings up the HHS’ total spending on the development of the V920 vaccine to a sum of $176 million.

The HHS is also funding the Department of Defense for its role in transporting vaccine production materials in bulk from their facilities in Germany to their plant in Pennsylvania.

More than 192,000 people have been vaccinated against Ebola with the V920 vaccine as of August 16 through compassionate use programmes, the HHS said.

The news comes as two new Ebola drugs proved 90% successful in treating Ebola in a multi-drug clinical trial.

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches